|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.08.26 - 23:00
|
Helix Biopharma Corp. Announces Board Composition Changes (The Newswire)
|
|
|
Vancouver, British Columbia; August 14, 2026 – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers, today announced changes to its Board of Directors (the “Board”), effective immediately.
Mr. Janusz Grabski has resigned from Helix's Board, with immediate effect. Concurrently, the Board has formally appointed Thomas Mehrling, M.D., Ph.D., Helix's Chief Executive Officer, as a director of the Company, pursuant to the Board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.1
Collectively, these changes are intended to ensure that the Board continues to meet Helix's evolving governance and capital markets requirements and has the composition and experience needed to support the Company...
|
|
|
14.08.26 - 23:00
|
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters′ Option to Purchase Additional ADSs (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--$SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,944,444 ADSs. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $201.3 million.
Jefferies, Morgan Stanley, Cantor and William Blair acted as joint book-running managers for the offering.
A shelf registration statement relating to the securities in the offering described above was filed with t...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.08.26 - 22:21
|
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to purchase an aggregate of 14,889 shares of common stock and inducement restricted stock units, covering an aggregate of 37,058 shares of its common stock.
The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.
The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing ...
|
|
|
14.08.26 - 22:09
|
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 (Business Wire)
|
|
|
EB-003 Development Highlights:
Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial
Reported preclinical data demonstrating that EB-003 consistently exhibited a non-hallucinogenic profile in a highly sensitive GloSensor™ assay, complementing previously reported BRET assay findings
Announced promising results from preclinical in vitro experiments indicating no photoreactive potential for EB-003, further derisking its continued development as a potential treatment of neuropsychiatric disorders
Initiated genotoxicity studies to evaluate the potential for EB-003 to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission
Corporate and Business Development Highlights:
Received a Notice of Allowance from the USPTO for a patent application covering the Company's EVM401 Series of methylone-inspired neuroplastogens
Secured U.S. Patent ...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
